Connect your AI

CG Oncology CGON Change in Other Liabilities

Change in Other Liabilities at other companies

PfizerPFE

-$916.75M-17.7%

Johnson & JohnsonJNJ

-$629M+90.3%

Cogent Biosciences, Inc.COGT

$29K+480%

Summit TherapeuticsSMMT

-$33K-232%

CRISPR TherapeuticsCRSP

-$199K+98.1%

BiogenBIIB

-$62M-38.8%

Other financials

Income statement

Revenue$1.1M+1,983%

Operating income-$66.4M-57.3%

Net income-$60.2M-74.7%

EPS (diluted)-$0.71-57.8%

Balance sheet

Cash & equivalents$33.7M-18.7%

Total debt$7.6M+631%

Total equity$1.1B+54.9%

Total assets$1.1B+55.9%

Cash flow

Operating cash flow-$56.9M-94.5%

CapEx$304.0K+1,800%

Free cash flow-$57.2M-95.4%

Valuation

Market cap$5.39B+206%

Enterprise value$5.36B+212%

P/S1,062.4×-1,596×

Profitability

Operating margin-4,239%-1,872pp

Net margin-3,682.6%-1,601pp

FCF margin-3,163.8%-1,351pp

Returns & leverage

Return on equity-20.8%+7.1pp

Debt / equity0×0.0×

Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's change in other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CG Oncology's change in other liabilities?: CG Oncology (CGON) reported change in other liabilities of -$329K in Q1 2026.
What does change in other liabilities mean?: Change in miscellaneous liabilities affecting operating cash flow.